Jazz Pharmaceuticals (JAZZ) Cash from Investing Activities (2010 - 2026)

Jazz Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $123.1 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 172.84% year-over-year to $123.1 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 200.48% YoY), while the FY2025 annual figure was -$1.5 billion, down 197.11% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $123.1 million, up from -$372.2 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $214.1 million in Q3 2024, with the low at -$641.0 million in Q2 2025.
• The 5-year median for Cash from Investing Activities is -$169.0 million (2025), against an average of -$147.3 million.
• Peak annual rise in Cash from Investing Activities reached 222.83% in 2024, while the deepest fall reached 5538.82% in 2024.
• Jazz Pharmaceuticals' Cash from Investing Activities stood at -$324.4 million in 2022, then soared by 131.38% to $101.8 million in 2023, then plunged by 289.87% to -$193.3 million in 2024, then tumbled by 92.54% to -$372.2 million in 2025, then surged by 133.08% to $123.1 million in 2026.
• Business Quant data shows JAZZ's Cash from Investing Activities at $123.1 million in Q1 2026, -$372.2 million in Q4 2025, and -$327.8 million in Q3 2025.